Vancouver, B.C., January 22, 2019 – Orion Nutraceuticals Inc., (CSE: ORI) (OTCQB: ORONF) (the “Company” or “Orion”) a cannabis life science company, is pleased to announce that theOTC Markets Group has approved the listing of the Company’s shares on its OTCQB Market under the ticker symbol “ORONF”. Trading will begin at market open on January 22, 2019. The Company’s common shares continue to trade on the Canadian Securities Exchange (the “CSE”) under the symbol “ORI”.

“We are excited to begin trading on the OTCQB Market and expand Orion Nutraceuticals presence in the United States,” said Jonathan Fiteni, CEO of Orion Nutraceuticals. “This exposure will put Orion in front of a broader range of institutional and retail investors in the United States and provide US investors with easy access to the Company’s securities through a recognized US marketplace. This is an important milestone in providing long-term value to our shareholders.”

About OTC Markets Group Inc.
OTC Markets Group Inc. provides services in three core areas: trading services, market data and corporate services. Through OTC Link® ATS, its SEC regulated Alternative Trading System, OTC Markets Group connects leading U.S. broker-dealers to provide liquidity & execution services for securities on its markets.

The OTCQB Venture Market offers early stage and developing international companies the benefits of being publicly traded in the U.S. with lower cost and complexity than a U.S. exchange listing. As a verified market with efficient access to U.S. investors, OTCQB helps international companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.

About Orion Nutraceuticals Inc.
Orion Nutraceuticals Inc. aims to set a new standard in cannabis life science by producing and developing innovative products with key strategic partners in the industry. In conjunction with its professional sports strategic alliances, the company is poised to advance research and development in the plant science sector, deliver science-based products and services, and market CBD therapies to the mainstream with proprietary brands and products. Medic-Oasis, Orion’s 99% held subsidiary, has submitted its application for an ACMPR license and is currently under review with Health Canada. Orion Nutraceuticals is partners with Colombian based medical cannabis corporation FCM Global. FCM Global supplies pharmaceutical, nutritional, wellness, and cosmetic companies in legal markets worldwide with customized medical cannabis extracts, oils, and isolates at commercial scale. FCM Global also collaborates with clients on research & development, conducting evidence-based pre-clinical and clinical trials.

On behalf of the Board of Directors
Jonathan Fiteni, CEO

Investor Relations
Robin Linden


This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.